{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:44Z","timestamp":1791618944418,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.eplepsyres.2020.106327","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T20:37:23Z","timestamp":1586464643000},"page":"106327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["A review of the drug\u2212drug interactions of the antiepileptic drug brivaracetam"],"prefix":"10.1016","volume":"163","author":[{"given":"Brian D.","family":"Moseley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Chanteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Laloyaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-5264","authenticated-orcid":false,"given":"Barry","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.eplepsyres.2020.106327_bib0005","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.seizure.2016.07.007","article-title":"Response to Zhang: Levetiracetam vs. brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison","volume":"41","author":"Borghs","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eplepsyres.2018.06.002","article-title":"Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program","volume":"145","author":"Brodie","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.12513","article-title":"Advances in epilepsy treatment: lacosamide pharmacokinetic profile","volume":"1329","author":"Cawello","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0030","article-title":"In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction and unrestricted brain permeability [poster 2.310]","author":"Chanteux","year":"2014","journal-title":"American Epilepsy Society Annual Meeting, December 5\u20139, 2014"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2020.106327_bib0035","first-page":"333","article-title":"In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction and unrestricted brain permeability [Abstract 2.310]","volume":"15","author":"Chanteux","year":"2015","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/03007995.2019.1584501","article-title":"Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis","volume":"35","author":"Charokopou","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0045","doi-asserted-by":"crossref","first-page":"10361","DOI":"10.1158\/0008-5472.CAN-06-4758","article-title":"Human pregnane X receptor and resistance to chemotherapy in prostate cancer","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/aps.2012.183","article-title":"Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats","volume":"34","author":"Chen","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2003.10","article-title":"Coordinate induction of both cytochrome P4503A and MDR1 by St John\u2019s wort in healthy subjects","volume":"73","author":"Dresser","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-199528030-00003","article-title":"Levonorgestrel. Clinical pharmacokinetics","volume":"28","author":"Fotherby","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0065","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00003088-199733030-00004","article-title":"Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation","volume":"33","author":"Glue","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0075","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0026-895X(25)13356-7","article-title":"Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450","volume":"33","author":"Guengerich","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/01.wnl.0000344167.78102.f0","article-title":"Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use","volume":"72","author":"Herzog","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0085","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/epi.13320","article-title":"Contraceptive practices of women with epilepsy: findings of the epilepsy birth control registry","volume":"57","author":"Herzog","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0090","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/157015910792246254","article-title":"Antiepileptic drug interactions - principles and clinical implications","volume":"8","author":"Johannessen","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0095","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0100","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0105","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/epi.16071","article-title":"Effects of cannabidiol on brivaracetam plasma levels","volume":"60","author":"Klotz","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond","volume":"30","author":"L\u00f6scher","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0115","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tort\u00f3s","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0120","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s11095-009-9961-8","article-title":"The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins","volume":"26","author":"Luna-Tort\u00f3s","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0125","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0130","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","article-title":"Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A","volume":"154","author":"Matagne","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0140","series-title":"American Epilepsy Society Annual Meeting","article-title":"The effect of brivaracetam on the pharmacokinetics of phenytoin: in vivo, in vitro, and modeling studies [Abstract 2.207]","author":"Moseley","year":"2016"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106218","article-title":"Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: pooled analysis of data from randomized clinical trials","volume":"158","author":"Moseley","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0150","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.112.045328","article-title":"Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects","volume":"40","author":"Nicolas","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/cpdd.275","article-title":"Relative bioavailability and bioequivalence of brivaracetam 10 mg\/mL oral solution and 50-mg film-coated tablet","volume":"6","author":"Otoul","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0170","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.103.049858","article-title":"Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity","volume":"306","author":"Potschka","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men","volume":"66","author":"Rolan","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2007.11.012","article-title":"Pharmacokinetic interactions between contraceptives and antiepileptic drugs","volume":"17","author":"Sabers","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0195","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects","volume":"36","author":"Sargentini-Maier","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl. 7","key":"10.1016\/j.eplepsyres.2020.106327_bib0205","first-page":"452","article-title":"Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects","volume":"49","author":"Sargentini-Maier","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0210","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/0091270011431457","article-title":"Brivaracetam disposition in renal impairment","volume":"52","author":"Sargentini-Maier","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0215","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jcph.761","article-title":"Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures","volume":"56","author":"Schoemaker","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eplepsyres.2017.09.014","article-title":"Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures","volume":"137","author":"Schoemaker","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00228-017-2230-6","article-title":"Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years","volume":"73","author":"Schoemaker","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40262-017-0597-2","article-title":"Extrapolation of a brivaracetam exposure-response model from adults to children with focal seizures","volume":"57","author":"Schoemaker","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0235","article-title":"Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? \u2013 A case series","volume":"159","author":"Steinhoff","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0240","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcph.187","article-title":"Effect of brivaracetam (400 mg\/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women","volume":"53","author":"Stockis","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0245","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jcph.82","article-title":"Brivaracetam disposition in mild to severe hepatic impairment","volume":"53","author":"Stockis","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0250","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/epi.12535","article-title":"Interaction between brivaracetam (100 mg\/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study","volume":"55","author":"Stockis","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0255","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2133\/dmpk.DMPK-14-RG-010","article-title":"Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype","volume":"29","author":"Stockis","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0260","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","article-title":"Brivaracetam and carbamazepine interaction in healthy subjects and in vitro","volume":"113","author":"Stockis","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0265","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jcph.446","article-title":"Effect of brivaracetam on CYP3A activity, measured by oral midazolam","volume":"55","author":"Stockis","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0270","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/epi.13433","article-title":"Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus","volume":"57","author":"Stockis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2016.11.001","article-title":"Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration","volume":"128","author":"Stockis","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0280","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.115.069161","article-title":"Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis","volume":"44","author":"Stockis","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0285","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0290","series-title":"BRIVIACT\u00ae (Brivaracetam) - US Prescribing Information","author":"UCB Inc","year":"2018"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0295","series-title":"BRIVIACT\u00ae (Brivaracetam) - EMA Summary of Product Characteristics","author":"UCB Pharma SA","year":"2018"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0300","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0305","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0310","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","article-title":"Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug","volume":"46","author":"Zhang","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0315","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106327_bib0320","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.seizure.2016.05.004","article-title":"Levetiracetam vs. brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison","volume":"39","author":"Zhang","year":"2016","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120300346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120300346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:02Z","timestamp":1760276642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121120300346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":64,"alternative-id":["S0920121120300346"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106327","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the drug\u2212drug interactions of the antiepileptic drug brivaracetam","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106327"}}